Tromantadine
(Synonyms: 曲金刚胺) 目录号 : GC32214
Tromantadine是一种单纯疱疹病毒(HSV)抑制剂。
Cas No.:53783-83-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment: | Confluent monolayers of Vero (2.4x106 per plate) or HEp-2 (1.6x106 per plate) cells are treated with various amounts of Tromantadine 15 min before and then throughout the infection and incubation. The dose of Tromantadine applied, rather than the concentration, is varied since, as for amantadine, the cells concentrate the compound from the medium. For most assays, cells are infected with 6x108 PFU of HSV-1 in 0.5 mL for 1 h at 37°C, and the virus solution is then aspirated off the monolayer and replaced with 2 mL of maintenance medium containing the same amount of the compound. The antiviral activity of the compounds is determined as a reduction in both virally induced cytopathic effect (CPE) and production of extracellular infectious virus 24, 48, and % h postinfection[1]. |
References: [1]. Rosenthal KS, et al. Tromantadine: inhibitor of early and late events in herpes simplex virus replication. Antimicrob Agents Chemother. 1982 Dec;22(6):1031-6. | |
Tromantadine is a herpes simplex virus (HSV) inhibitor.
Tromantadine inhibits herpes simplex virus type 1 (KOS strain)-induced cytopathic effect and virus replication with limited toxicity to the cells. Vero and HEp-2 cells tolerate up to 2 mg of Tromantadine per 2x106 cells for 24-, 48-, or 96-h incubation periods with little change in cell morphology. Treatment of the cells with 10 to 50 μg of Tromantadine reduces herpes simplex virus-induced cytopathic effect. Treatment with 100 to 500 μg of Tromantadine inhibits herpes simplex virus-induced cytopathic effect and reduces virus production. Complete inhibition of virus production is observed with treatments of 500 μg to 1 mg. The antiherpetic activity of Tromantadine is dependent upon the viral inoculum size and the time of addition of the compound with respect to infection. Virion synthesis and viral polypeptide synthesis are inhibited by addition of Tromantadine at the time of infection or 4 h postinfection[1]. Tromantadine raises the bilayer to hexagonal phase transition temperature of synthetic phosphatidylethanolamines and is less disruptive to phospholipid packing. Tromantadine acts similar to cyclosporin A, previously demonstrated to inhibit viral-induced cell-cell fusion[2].
[1]. Rosenthal KS, et al. Tromantadine: inhibitor of early and late events in herpes simplex virus replication. Antimicrob Agents Chemother. 1982 Dec;22(6):1031-6. [2]. Cheetham JJ, et al. Comparison of the interaction of the anti-viral chemotherapeutic agents amantadine and tromantadine with model phospholipid membranes. Biosci Rep. 1987 Mar;7(3):225-30.
| Cas No. | 53783-83-8 | SDF | |
| 别名 | 曲金刚胺 | ||
| Canonical SMILES | O=C(COCCN(C)C)NC1(C[C@H](C2)C3)C[C@H]3C[C@H]2C1 | ||
| 分子式 | C16H28N2O2 | 分子量 | 280.41 |
| 溶解度 | Soluble in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5662 mL | 17.831 mL | 35.6621 mL |
| 5 mM | 0.7132 mL | 3.5662 mL | 7.1324 mL |
| 10 mM | 0.3566 mL | 1.7831 mL | 3.5662 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Tromantadine: inhibitor of early and late events in herpes simplex virus replication
Antimicrob Agents Chemother 1982 Dec;22(6):1031-6.PMID:6297383DOI:10.1128/AAC.22.6.1031.
Unlike amantadine (1-adamantanamine), Tromantadine (N-1-adamantyl-N-[2-(dimethyl amino)ethoxy]acetamide hydrochloride) inhibits herpes simplex virus type 1 (KOS strain)-induced cytopathic effect and virus replication with limited toxicity to the cells. Vero and HEp-2 cells tolerated up to 2 mg of Tromantadine per 2 X 10(6) cells for 24-, 48-, or 96-h incubation periods with little change in cell morphology. Treatment of the cells with 10 to 50 micrograms of Tromantadine reduced herpes simplex virus-induced cytopathic effect. Treatment with 100 to 500 micrograms of Tromantadine inhibited herpes simplex virus-induced cytopathic effect and reduced virus production. Complete inhibition of virus production was observed with treatments of 500 micrograms to 1 mg. The antiherpetic activity of Tromantadine was dependent upon the viral inoculum size and the time of addition of the compound with respect to infection. Virion synthesis and viral polypeptide synthesis were inhibited by addition of Tromantadine at the time of infection or 4 h postinfection. The results are consistent with Tromantadine inhibition of an early event in herpes simplex virus infection, before macromolecular synthesis, and a late event, such as assembly or release of virus.
Tromantadine inhibits a late step in herpes simplex virus type 1 replication and syncytium formation
Antiviral Res 1990 Aug;14(2):75-85.PMID:2177318DOI:10.1016/0166-3542(90)90045-9.
Addition of Tromantadine after virus penetration inhibited HSV-1 induced syncytium formation and virus production in HEp-2 and VERO cells and acted additively with neutralizing antibody in blocking virus spread and cytopathology. Inhibition of syncytium formation in VERO cells infected with 0.01 pfu/cell of HSV-1 GC+ was observed at a concentration greater than 25 micrograms/ml. The extent of inhibition was dependent upon the multiplicity of infection and cell type. Tromantadine inhibited a late event in HSV-1 replication which appeared to be sensitive to cycloheximide. Reversal of the inhibitory effect of Tromantadine on syncytium formation required new protein synthesis. HSV-1 gB, gC, and gD were synthesized in the presence of Tromantadine and could be detected on the cell surface by immunofluorescence. Tromantadine most likely inhibits a cellular process that is required for syncytium formation, such as glycoprotein processing, which occurs after the synthesis of the fusion protein but before its expression on the cell surface.
The metabolism of Tromantadine
Biomed Mass Spectrom 1985 Sep;12(9):487-8.PMID:2932176doi
The metabolism of the antiviral drug Tromantadine (1-adamantyl-2-(2-dimethylaminoethoxy)acetamide) was studied after an oral dose of 120 mg Tromantadine hydrochloride using capillary gas chromatography/mass spectrometry. Most of the dose was excreted unchanged with the urine. Six metabolites could be identified. The main metabolic products were 1-aminoadamantane (amantadine) and 1-adamantyl-(2-hydroxy)acetamide. Further metabolic pathways were demethylation of the dimethylamino function and oxidative desamination to an unstable aldehyde which is oxidized to a carbonic acid or reduced to an alcohol.
[Contact allergy to Tromantadine]
Derm Beruf Umwelt 1984;32(5):157-60.PMID:6239766doi
Though infection with herpes simplex virus is one of the most common infections, there has not been causal topical treatment until now. Since 1973 Tromantadine HCl (in the following briefly called Tromantadine) has been offered as a topical virustatic agent. Only three years later, in 1976, there were the first reports of allergic contact dermatitis due to Tromantadine. 19 patients with dermatitis after application of Tromantadine ointment were patch-tested and in 14 of them a contact allergy to Tromantadine was observed. In 119 patients who were patch-tested because of various dermatoses, Tromantadine and the gel base were patch-tested additionally. Two positive reactions to the active substance and two to the gel base only were found. One of the latter patients also had a positive reaction to parabens. The results are discussed and compared with the results of other authors.
Allergic contact dermatitis from Tromantadine
J Investig Allergol Clin Immunol 1997 Jul-Aug;7(4):260-1.PMID:9330192doi
Tromantadine is a topical antiviral agent derived from amantadine. In previous reports, 5% of treated patients developed contact allergy. We report the case of a 28-year-old woman who had a sudden worsening of a lip herpes after treatment with a Tromantadine ointment, with strong positive patch testing to this substance. The purpose of this paper is to call attention to the fact that Tromantadine is still widely used in several European countries as a second-line therapy for lip herpes, and therefore, new cases of sensitization to Tromantadine are likely to occur.